این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Iranian Journal of Pediatric Hematology and Oncology، جلد ۷، شماره ۴، صفحات ۲۰۷-۲۱۵
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Evaluating Protective Effects of Silymarin on Liver and Cardiac Side Effects of Chemotherapy Drugs in Childhood Acute Lymphoblastic Leukemia
چکیده انگلیسی مقاله Background: The protective effects of silymarin on liver and heart have been investigated and identified by many researchers. This study evaluates the protective effects of this substance on hepatotoxicity and cardiotoxcity of chemotherapy drugs in leukemic children. Materials and Methods: In this study, 71 children, aging 2-14 years old, going through the maintenance phase of acute lymphoblastic leukemia (ALL) treatment at Children's Cancer Center of Isfahan University of Medical Sciences (Iran) in 2015 were studied. Two patients died and the remaining patients were divided into intervention and control groups. Intervention group received Mercaptopurin and Methotrexate plus Silymarin 140mg/day and control group were taking only Mercaptopurin and Methotrexate. Liver enzymes, Coagulation tests, Creatine kinase- Muscle and Brain (CK-MB), Ejection fraction and Systolic function (SF) were measured at the first, and 3 and 6 months' intervals from the commencement of study. The Data was analyzed by using SPSS and P ≤ 0.05 was considered as statistically significant. Associations between variables were analyzed using independent t-test, chi square, and repeated measures ANOVA test. Results: Mean levels of Alanine aminotransferase in both groups increased significantly at 6 months interval (P=0.01, 0.01, for control and intervention groups respectively). Although increment was more among controls, there were no significant differences between the two groups (P= 0.85). Furthermore, Aspartate aminotransferase and Alkaline phosphatase increased in both groups and the increment was significant in the controls (P=0.001, 0.05, for control and intervention groups respectively). Coagulation tests prolonged in the first 3 months in both groups and the prolongation was more in control group. Changes in CK-MB were not significant in intervention and controls (P=0.07, 0.10, respectively) but ejection fraction and SF decreased in both groups, especially among controls. Conclusion: It seems that Silymarin can be useful in prevention of hepatotoxicity and cardiotoxcity of chemotherapy drugs for ALL children. 
کلیدواژه‌های انگلیسی مقاله
نویسندگان مقاله مهدی قادریان | mehdi ghaderian
assistant professor of pediatric cardiology, isfahan university of medical sciences, isfahan, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی اصفهان (Isfahan university of medical sciences)

ناهید رییسی | nahid reisi
associate professor of pediatric hematology and oncology, faculty of child growth development research center and isfahan immunodeficiency research center, isfahan university of medical sciences, isfahan, iran.

سازمان اصلی تایید شده: دانشگاه علوم پزشکی اصفهان (Isfahan university of medical sciences)

علیرضا معافی | alireza moafi
associate professor of pediatric hematology and oncology, isfahan university of medical sciences, isfahan, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی اصفهان (Isfahan university of medical sciences)

صفورا فراست | safora farasat
assistant professor of pediatrics, isfahan university of medical sciences, isfahan, iran.

سازمان اصلی تایید شده: دانشگاه علوم پزشکی اصفهان (Isfahan university of medical sciences)

نشانی اینترنتی http://ijpho.ssu.ac.ir/browse.php?a_code=A-10-396-2&slc_lang=en&sid=en
فایل مقاله اشکال در دسترسی به فایل - ./files/site1/rds_journals/202/article-202-449164.pdf
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده 1
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات